Dustin Deming, MD
Medical Oncology · Madison, WINPI 1831393883
Payments from drug & device makers
Across 254 payments — averaging $31,906 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$2.6M
- Merck$1.7M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Eli Lilly$1M
- Aadi Bioscience, Inc.$783K
- Pfizer$511K
- plus $465K from 18 others
Across 1 payment — averaging $330.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$330
What the payments were for
- Consulting fees$59,47559%
- Speaking & faculty fees$33,25833%
- Travel & lodging$4,1964%
- Food & beverage$3,0063%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 21 | $2,560,953 |
| Merck | 16 | $1,677,720 |
| E.r. Squibb & Sons, L.L.C. | 39 | $1,058,374 |
| Eli Lilly | 8 | $1,048,467 |
| Aadi Bioscience, Inc. | 33 | $782,802 |
| Pfizer | 48 | $510,824 |
| Array Biopharma Inc | 18 | $124,052 |
| Biontech SE | 18 | $107,110 |
| Promega Corporation | 2 | $59,571 |
| Taiho Oncology, Inc. | 12 | $38,726 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37,956 |
| AbbVie | 3 | $34,613 |
| Genentech, Inc. | 2 | $22,000 |
| Regeneron | 7 | $8,869 |
| Bayer | 4 | $8,000 |
| Lilly USA, LLC | 1 | $4,900 |
| Seagen Inc. | 2 | $4,239 |
| Novocure Inc. | 6 | $3,395 |
| Exelixis Inc. | 2 | $3,300 |
| GSK | 2 | $2,800 |
| Illumina, Inc. | 1 | $2,226 |
| Aurobindo Pharma USA, Inc. | 1 | $1,500 |
| Foundation Medicine, Inc. | 2 | $1,298 |
| Genentech USA, Inc. | 3 | $360 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRAFTOVI$17,583
- Vitrakvi$8,000
- TUKYSA$4,239
- MEKTOVI$3,950
- LIBTAYO$3,427
- Cabometyx$3,300
- Oncology$3,222
- Oncology Testing$2,226
- Lonsurf$1,868
- Khapzory$1,500
- FOUNDATIONONE CDX$865
- FOUNDATIONONE LIQUID CDX$433
- Avastin$360
- ONIVYDE$100
How this compares
$8,104,054 in reported general payments places this provider in the 95th percentile of 54 medical oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 47 | $601 |
| Ondansetron Hcl | 47 | $297 |
| Pantoprazole Sodium | 11 | $184 |
| Prochlorperazine Maleate | 21 | $160 |
| Gabapentin | 13 | $153 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Madison
- Kari WisinskiMadison$6.8M
- Glenn LiuMadison$3.4M
- Justine BruceMadison$3M
- Douglas McNeelMadison$926K
- Toby CampbellMadison$641K
- Joshua LangMadison$634K
- Mark AlbertiniMadison$553K
- Malinda WestMadison$533K
- Howard BaileyMadison$380K
- Anne TraynorMadison$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.